Legacy methods like microarrays and bisulfite sequencing lack the resolution and scalability needed for clinical impact, limiting biomarker discovery and slowing adoption in precision health. Wasatch BioLabs’ Direct Whole Methylome (dWMS) platform is a nanopore-based solution optimized through proprietary library preparation and dWMS-specific bioinformatics. By building on the core strengths of Oxford Nanopore Technologies, dWMS delivers high-resolution, end-to-end methylation and variant analysis designed for real-world research and clinical use.